Yves Pommier

79.6k total citations · 20 hit papers
870 papers, 62.2k citations indexed

About

Yves Pommier is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Yves Pommier has authored 870 papers receiving a total of 62.2k indexed citations (citations by other indexed papers that have themselves been cited), including 764 papers in Molecular Biology, 293 papers in Oncology and 151 papers in Infectious Diseases. Recurrent topics in Yves Pommier's work include Cancer therapeutics and mechanisms (495 papers), DNA Repair Mechanisms (203 papers) and HIV/AIDS drug development and treatment (151 papers) Yves Pommier is often cited by papers focused on Cancer therapeutics and mechanisms (495 papers), DNA Repair Mechanisms (203 papers) and HIV/AIDS drug development and treatment (151 papers) Yves Pommier collaborates with scholars based in United States, Japan and France Yves Pommier's co-authors include Kurt W. Kohn, Christophe Marchand, Glenda Kohlhagen, Junko Murai, Mark Cushman, Philippe Pourquier, William C. Reinhold, James H. Doroshow, Donna Kerrigan and Abhijit Mazumder and has published in prestigious journals such as Science, Cell and Chemical Reviews.

In The Last Decade

Yves Pommier

857 papers receiving 61.1k citations

Hit Papers

Topoisomerase I inhibitors: camptothecins and ... 1989 2026 2001 2013 2006 2012 2010 2008 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Topoisomerase I inhibitors: camptothecins and beyond
    2006 1.8k citations Yves Pommier profile →
  2. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
    2012 1.6k citations Junko Murai, James H. Doroshow et al. Cancer Research profile →
  3. DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
    2010 1.5k citations Yves Pommier, Christophe Marchand et al. profile →
  4. γH2AX and cancer
    2008 1.3k citations William M. Bonner, Asako Nakamura et al. profile →
  5. A gene expression database for the molecular pharmacology of cancer
    2000 1.1k citations Kurt W. Kohn, William C. Reinhold et al. profile →
  6. Drugging Topoisomerases: Lessons and Challenges
    2012 674 citations Yves Pommier profile →
  7. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
    2016 654 citations Yves Pommier, Yilun Sun et al. profile →
  8. CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set
    2012 635 citations William C. Reinhold, Margot Sunshine et al. Cancer Research profile →
  9. Initiation of DNA Fragmentation during Apoptosis Induces Phosphorylation of H2AX Histone at Serine 139
    2000 612 citations Yves Pommier, William M. Bonner et al. profile →
  10. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
    2013 592 citations Junko Murai, Shar-yin N. Huang et al. Molecular Cancer Therapeutics profile →
  11. DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
    2009 575 citations Yves Pommier profile →
  12. Integrase inhibitors to treat HIV/Aids
    2005 562 citations Yves Pommier, Christophe Marchand et al. profile →
  13. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
    2016 540 citations Yves Pommier et al. profile →
  14. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
    2004 469 citations Yves Pommier, Kurt W. Kohn et al. profile →
  15. Induction of a Common Pathway of Apoptosis by Staurosporine
    1994 452 citations Kurt W. Kohn, Yves Pommier et al. profile →
  16. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
    1989 401 citations Kurt W. Kohn, Yves Pommier et al. profile →
  17. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
    2017 379 citations Junko Murai, Yves Pommier et al. profile →
  18. Inhibition of human immunodeficiency virus type-1 integrase by curcumin
    1995 304 citations John N. Weinstein, Kurt W. Kohn et al. profile →
  19. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds
    1994 292 citations Yves Pommier, Kurt W. Kohn et al. profile →
  20. Human topoisomerases and their roles in genome stability and organization
    2022 238 citations Yves Pommier, Shunichi Takeda et al. profile →

Peers

Yves Pommier
Comparison fields: 5 of 182
  • Molecular Biology 48.2k
  • Oncology 21.0k
  • Organic Chemistry 9.6k
  • Toxicology 6.5k
  • Cancer Research 6.2k
Replace Ting‐Chao Chou with:
Ting‐Chao Chou United States
Michael M. Gottesman United States
Stuart L. Schreiber United States
David S. Goodsell United States
Garrett M. Morris United Kingdom
Randy J. Read United Kingdom
Michael R. Boyd United States
Olivier Michielin Switzerland
Paul D. Adams United States
Robert H. Shoemaker United States
Ting‐Chao Chou United States View profile →
Citations per field, relative to Yves Pommier
Yves Pommier · 1×
Citations per year, relative to Yves Pommier
Yves Pommier · 1×

Countries citing papers authored by Yves Pommier

Since Specialization
Citations

This map shows the geographic impact of Yves Pommier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Pommier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Pommier more than expected).

Fields of papers citing papers by Yves Pommier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Pommier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Pommier. The network helps show where Yves Pommier may publish in the future.

Co-authorship network of co-authors of Yves Pommier

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Pommier. A scholar is included among the top collaborators of Yves Pommier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Pommier. Yves Pommier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II
2022 ·Molecular Cancer Therapeutics ·Yilun Sun, (unknown), Christopher W. Schultz, Yves Pommier, Anish Thomas
9
2
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM -Deficient Tumors and Potent Synergy With PARP Inhibitors
2022 ·Molecular Cancer Therapeutics ·Anish Thomas, Shaun D. Fontaine, Morgan E. Diolaiti, Parth Desai, Rajesh Kumar, Nobuyuki Takahashi, Linda Sciuto, Samantha Nichols, Alan Ashworth, Felix Y. Feng, Gary W. Ashley, Minh Nguyen, Yves Pommier, Daniel V. Santi
7
3
Targeting Topoisomerase I in the Era of Precision Medicine
2019 ·Clinical Cancer Research ·Anish Thomas, Yves Pommier
195
4
Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2018 ·Molecular Cancer Therapeutics ·Laetitia Marzi, Keli Agama, Junko Murai, Simone Difilippantonio, (unknown), Cody J. Peer, William D. Figg, (unknown), Mohamed Elsayed, Mark Cushman, Yves Pommier
32
5
Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
2016 ·Clinical Cancer Research ·(unknown), Sylvain Thierry, (unknown), Flavien Devun, Muthana Al Abo, (unknown), Jian‐Sheng Sun, Emmanuel Barillot, Andreï Zinovyev, Inna Kuperstein, Yves Pommier, Marie Dutreix
29
6
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60
2015 ·Clinical Cancer Research ·William C. Reinhold, Margot Sunshine, Sudhir Varma, James H. Doroshow, Yves Pommier
79
7
Biochemical Assays for the Discovery of TDP1 Inhibitors
2014 ·Molecular Cancer Therapeutics ·Christophe Marchand, Shar-yin N. Huang, Thomas S. Dexheimer, Wendy Lea, Bryan T. Mott, Adel Chergui, (unknown), Andrew G. Stephen, Andrew S. Rosenthal, Ganesha Rai, Junko Murai, Rui Gao, David J. Maloney, Ajit Jadhav, William L. Jorgensen, Anton Simeonov, Yves Pommier
17
8
Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
2014 ·Clinical Cancer Research ·Salim Khiati, Ilaria Dalla Rosa, Carole Sourbier, Xuefei Ma, V. Ashutosh Rao, Leonard Μ. Neckers, Hongliang Zhang, Yves Pommier
101
9
Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
2013 ·Molecular Cancer Therapeutics ·(unknown), Hiroyasu Shimizu, Toru Fukushima, Toshiaki Kogame, Terukazu Nakamura, Tsuneharu Miki, Shunichi Takeda, Yves Pommier, Junko Murai
106
10
Transcription Poisoning by Topoisomerase I Is Controlled by Gene Length, Splice Sites, and miR-142-3p
2013 ·Cancer Research ·Stéphanie Solier, Michaël Ryan, Scott E. Martin, Sudhir Varma, Kurt W. Kohn, Hongfang Liu, Barry R. Zeebèrg, Yves Pommier
38
11
Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response
2012 ·Proceedings of the National Academy of Sciences ·Stéphanie Solier, Kurt W. Kohn, Bradley T. Scroggins, Wanping Xu, Jane B. Trepel, Leonard Μ. Neckers, Yves Pommier
74
12
Probing chelation motifs in HIV integrase inhibitors
2012 ·Proceedings of the National Academy of Sciences ·Arpita Agrawal, (unknown), (unknown), Kasthuraiah Maddali, (unknown), Douglas D. Richman, Yves Pommier, Seth M. Cohen
40
13
Exon Array Analyses across the NCI-60 Reveal Potential Regulation of TOP1 by Transcription Pausing at Guanosine Quartets in the First Intron
2010 ·Cancer Research ·William C. Reinhold, Jean‐Louis Mergny, Hongfang Liu, Michaël Ryan, Thomas D. Pfister, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, John N. Weinstein, Yves Pommier
60
14
Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
2010 ·Clinical Cancer Research ·Robert J. Kinders, Melinda G. Hollingshead, Scott M. Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
56
15
MDC1 Cleavage by Caspase-3: A Novel Mechanism for Inactivating the DNA Damage Response during Apoptosis
2010 ·Cancer Research ·Stéphanie Solier, Yves Pommier
30
16
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
2009 ·Molecular Cancer Therapeutics ·Thomas D. Pfister, William C. Reinhold, Keli Agama, Shalu Gupta, Sonny Khin, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Yves Pommier
126
17
Par-4 Binds to Topoisomerase 1 and Attenuates Its DNA Relaxation Activity
2008 ·Cancer Research ·Anindya Goswami, Shirley Qiu, Thomas S. Dexheimer, (unknown), Ravshan Burikhanov, Yves Pommier, Vivek M. Rangnekar
27
18
Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses
2007 ·Cancer Research ·Ze-Hong Miao, Audrey Player, Uma Shankavaram, (unknown), Drazen B. Zimonjic, Philip L. Lorenzi, (unknown), Hong Liu, Tsutomu Shimura, (unknown), (unknown), Yongwei Zhang, Ernest S. Kawasaki, Nicholas C. Popescu, Mirit I. Aladjem, D. Goldstein, John N. Weinstein, Yves Pommier
79
19
Endogenous γ-H2AX-ATM-Chk2 Checkpoint Activation in Bloom's Syndrome Helicase–Deficient Cells Is Related to DNA Replication Arrested Forks
2007 ·Molecular Cancer Research ·V. Ashutosh Rao, Chiara Conti, Josée Guirouilh‐Barbat, Asako Nakamura, Ze‐Hong Miao, (unknown), Barbara Saccà, Ian D. Hickson, Aaron Bensimon, Yves Pommier
76
20
Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors
2006 ·Clinical Cancer Research ·Yves Pommier, John N. Weinstein, Mirit I. Aladjem, Kurt W. Kohn
69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ting‐Chao Chou Breakdown of academic impact, for papers by Michael M. Gottesman Breakdown of academic impact, for papers by Stuart L. Schreiber Breakdown of academic impact, for papers by David S. Goodsell Breakdown of academic impact, for papers by Garrett M. Morris Breakdown of academic impact, for papers by Randy J. Read Breakdown of academic impact, for papers by Michael R. Boyd Breakdown of academic impact, for papers by Olivier Michielin Breakdown of academic impact, for papers by Paul D. Adams Breakdown of academic impact, for papers by Robert H. Shoemaker
Rankless by CCL
2026